Methadone Fights Addiction, Helps in Other Ways Too

The powerful drug methadone not only helps those addicted to heroin and morphine leave their drug abuse behind, it also has additional health benefits. Recent studies show that methadone  helps reduce the risk of HIV transmission among drug users. The British Medical Journal reported that people who inject drugs (PWID) benefit from treatment with methadone in more ways than one.

It does substitute for opiate injections and helps reduce cravings for more dangerous drugs since it mimics opiates’ stimulus to the brain without providing as powerful a high as street drugs such as heroin. At the same time, its use can supplant injections and thus reduce the risks of transmitting HIV by contaminated needles. Methadone as a substitute for opiates improves the health of those taking it.

The researchers concluded that drug-related deaths decreased when drug users were prescribed methadone. It has become hugely popular and reliable as a treatment of choice for chronic drug abusers and addicts. The reduction of HIV transmission is a bonus not originally considered when methadone first came into widespread use.

Incidence of HIV in drug injectors who live in countries where opiate substitution therapy is illegal showed to be measurably higher than in those who reside in countries where methadone and other substitutes can be prescribed. Worldwide statistics show that approximately 5-10 percent of HIV infections come about because of injection of drugs. AIDS is also higher in parts of the world where drug substitution treatment is highly restricted.

Health care professionals most often prescribe methadone or buprenorphine as substitutes for illegal opiates such as heroin and morphine. The substitutes are generally given in treatment centers, clinics, and physicians’ offices. They affect similar parts of the brain and help ease the addict off the street drug without the harsh symptoms of drug withdrawal.

The recent research on methadone’s effectiveness in helping to curb the spread of HIV and AIDS resulted from a collaboration of scientists from several different countries. Researchers from the U.S., Australia, Italy and Canada reviewed available literature, then pooled their analyses. They studied work from their own countries as well as from the Netherlands, Austria, Puerto Rico, Thailand and China.

The work focused on the connection between opiate substitution therapy and HIV transmission. Researchers selected nine studies that concentrated mostly on male injection drug users between the ages of 26 and 39. Among the study group, there were 819 HIV infection transmissions. The study covered a time period of 23,608 total person years of study.

Analysis showed that opiate substitutes such as methadone were linked to a 54 percent decrease in HIV infection risk among drug users used to injecting their fixes. Since the data came from nations around the world, there was some variation in the individual studies. This disallowed an exact result.

Nonetheless, the study was strong enough to show a clear-cut link between methadone use substituted for opiate injection and a reduction in HIV. Medical workers around the world were given another solid reason for recommending methadone treatment to injection drug users as a way to kick the habit and get healthier.

The research seemed to suggest that longer-term use of methadone results in an even lower risk of HIV transmission among former needle drug users. Commentators on the research have spoken out strongly in favor of opiate substitution therapies as a way to curb the growing number of HIV infections spread by needle users. This seems to be the case in all parts of the world.

Other research has suggested that methadone may have benefits in treatment resistant forms of cancer. There will be years of further study ahead, but preliminary studies show that methadone can fight leukemia cells. The professional journal Cancer Research published the report that provided a little hope to patients with cancer that is no longer responding to radiation and chemotherapy.

One of the study’s authors commented that methadone was shown to kill sensitive leukemia cells. It was also shown to break through cancer treatment resistance that has built up in cancer cells. It seemed to go after the cancer without damaging healthy cells untouched by cancer.

Researchers are reluctant to give false hope to people with cancer. They stress that this report is preliminary. Yet it does offer hope for the possibly near future.

Proponents of methadone are naturally pleased that the opiate substitute may have wider applications in the field of medicine well beyond its prime use as a helper in the fight against drug addiction.

In recent years methadone has come under attack for its possibly harmful side effects in those who take it for extended periods. As with almost every drug or medicine, problems show up after the using population has grown large enough that trends can be observed. Nonetheless, methadone remains an important and helpful medicine in today’s world.

 

Buprenorphine + Naloxone plus Naltrexone for the Treatment of Cocaine Dependence: The Cocaine Use Reduction with Buprenorphine (CURB) Study

ConclusionsBuprenorphine + naloxone, used in combination with naltrexone, may be associated with reductions in cocaine use among people who meet DSM‐IV criteria for cocaine dependence and past or current opioid dependence or abuse. This article is protected by copyright. All rights reserved. (Source: Addiction)

MedWorm Sponsor Message: Directory of the best January Sales in the UK. Find the best Christmas presents too.

Letter Reveals Drug Courts Lobbied Against Key Addiction Treatment

WASHINGTON – The head of a nonprofit organization that represents drug courts lobbied the U.S. Department of Health and Human Services against increasing access to a key addiction treatment. In an Aug. 19, 2014, letter obtained by The Huffington Post through an open records request, West Huddleston, the then-CEO of the National Association of Drug Court Professionals, wrote HHS Secretary Sylvia Mathews Burwell and urged her to keep strict caps on the number of opioid addicts doctors can treat with buprenorphine. Use of the medication along with counseling, known as medication-assisted treatment, is considered by public health officials to give opioid addicts the best chance at a recovery. But many drug court judges have opposed the treatment, insisting defendants go cold turkey …

MedWorm Sponsor Message: Directory of the best January Sales in the UK. Find the best Christmas presents too.

Letter Reveals Drug Courts Lobbied Against Key Addiction Treatment

WASHINGTON – The head of a nonprofit organization that represents drug courts lobbied the U.S. Department of Health and Human Services against increasing access to a key addiction treatment. In an Aug. 19, 2014, letter obtained by The Huffington Post through an open records request, West Huddleston, the then-CEO of the National Association of Drug Court Professionals, wrote HHS Secretary Sylvia Mathews Burwell and urged her to keep strict caps on the number of opioid addicts doctors can treat with buprenorphine. Use of the medication along with counseling, known as medication-assisted treatment, is considered by public health officials to give opioid addicts the best chance at a recovery. But many drug court judges have opposed the treatment, insisting defendants go cold turkey …

MedWorm Sponsor Message: Directory of the best January Sales in the UK. Find the best Christmas presents too.

W-18, a synthetic opiate 100 times more potent than fentanyl

W-18
Last August, Canadian police seized 110 illegal fentanyl pills at a home in Alberta province. Yesterday, Global News reported that some of the pills have tested positive for an extremely potent opioid called W-18.
This is certainly a disturbing development, since W-18 is a μ-receptor agonist 100 times more potent than fentanyl. According to B.C. Centre for Disease Control, W-18 is one of a series of 32 synthetic opioids discovered in the 1980s at the University of Alberta. W1 thru W19 are pure μ-receptor agonists; W20 thru W32 are agonist-antagonists (as is buprenorphine.)  W-18 seems to be the most powerful agonist of the group.
The ‘W’ compounds have never been used clinically, and there has been virtually no scientific study of their actions, adverse effects, or reve…

W-18, a synthetic opiate 100 times more potent than fentanyl

W-18
Last August, Canadian police seized 110 illegal fentanyl pills at a home in Alberta province. Yesterday, Global News reported that some of the pills have tested positive for an extremely potent opioid called W-18.
This is certainly a disturbing development, since W-18 is a μ-receptor agonist 100 times more potent than fentanyl. According to B.C. Centre for Disease Control, W-18 is one of a series of 32 synthetic opioids discovered in the 1980s at the University of Alberta. W1 thru W19 are pure μ-receptor agonists; W20 thru W32 are agonist-antagonists (as is buprenorphine.)  W-18 seems to be the most powerful agonist of the group.
The ‘W’ compounds have never been used clinically, and there has been virtually no scientific study of their actions, adverse effects, or reve…

MedWorm Sponsor Message: Directory of the best January Sales in the UK. Find the best Christmas presents too.

Presence or Absence of QTc Prolongation in Buprenorphine-Naloxone Among Youth With Opioid Dependence

Objectives: The aim of the study was to evaluate buprenorphine-naloxone effects on the QTc in youth with opioid dependence. Buprenorphine is a partial agonist that is an effective treatment for opioid dependence. Compared with methadone, it has a lower risk of QTc prolongation in adults, but is less studied in the youth. It may also reduce the risk of torsades de pointes (TdP)—an uncommon variant of polymorphic ventricular tachycardia—that can result in syncope, ventricular fibrillation, and sudden death.
Methods: Secondary analysis of the electrocardiogram data from 95 individuals who participated in a multisite trial for youth with opioid dependence. The participants were randomized to a 2-week (DETOX) or a 12-week course of buprenorphine-naloxone (BUP). At baseline, 12-lead electro…

Presence or Absence of QTc Prolongation in Buprenorphine-Naloxone Among Youth With Opioid Dependence

Objectives: The aim of the study was to evaluate buprenorphine-naloxone effects on the QTc in youth with opioid dependence. Buprenorphine is a partial agonist that is an effective treatment for opioid dependence. Compared with methadone, it has a lower risk of QTc prolongation in adults, but is less studied in the youth. It may also reduce the risk of torsades de pointes (TdP)—an uncommon variant of polymorphic ventricular tachycardia—that can result in syncope, ventricular fibrillation, and sudden death.
Methods: Secondary analysis of the electrocardiogram data from 95 individuals who participated in a multisite trial for youth with opioid dependence. The participants were randomized to a 2-week (DETOX) or a 12-week course of buprenorphine-naloxone (BUP). At baseline, 12-lead electro…